(3-chloro-benzyl)-methyl sulfone | 22539-18-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-chloro-benzyl)-methyl sulfone
• 英文别名: (3-Chlor-benzyl)-methyl-sulfon；1-Chloro-3-methanesulfonylmethyl-benZene；1-chloro-3-(methylsulfonylmethyl)benzene
• CAS: 22539-18-0
• 化学式: C₈H₉ClO₂S
• 分子量: 204.677
• InChiKey: YZKPPPVDBLMXSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-chloro-benzyl)-methyl sulfone 在 sodium amide 、 甲苯 作用下， 生成 2-(3-chloro-α-methanesulfonyl-benzyl)-pyridine
  参考文献：
  名称：

  Alkyl Phenyl-(2-pyridyl)-methyl Sulfones. Sulfonium Salts as Alkylating Agents

  摘要：

  DOI：

  10.1021/ja01149a059
• 作为产物：
  描述：

  溴甲烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 作用下， 生成 (3-chloro-benzyl)-methyl sulfone
  参考文献：
  名称：

  Alkyl Phenyl-(2-pyridyl)-methyl Sulfones. Sulfonium Salts as Alkylating Agents

  摘要：

  DOI：

  10.1021/ja01149a059

文献信息

• Azetidine derivatives, their preparation and medicaments containing them
  申请人：——

  公开号：US20020035102A1

  公开（公告）日：2002-03-21

  The invention concerns compounds of formula (1) wherein: R represents a chain (A) or (B); R 1 is methyl or ethyl; R 2 is either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R 3 and R 4 , identical or different, are either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R′ represents a hydrogen atom or a —CO—alk radical, their optical isomers, their salts, their preparation and medicines containing them. 1

  本发明涉及通式(1)的化合物，其中：R代表链(A)或(B)；R1是甲基或乙基；R2是可任选取代的芳香环或可任选取代的杂芳香环；R3和R4，相同或不同，是可任选取代的芳香环或可任选取代的杂芳香环；R′代表氢原子或—CO—烷基，它们的光学异构体，它们的盐，它们的制备方法以及含有它们的药物。
• [EN] AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES AMIDINO SERVANT D'INHIBITEURS DE PROTEASES A CYSTEINE
  申请人：AXYS PHARMACEUTICALS

  公开号：WO2004108661A1

  公开（公告）日：2004-12-16

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是包括B、K、L、F和S半胱氨酸蛋白酶，因此在治疗由这些蛋白酶介导的疾病方面具有用处。本发明涉及包含这些化合物的药物组合物以及其制备方法。
• [EN] HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES CONTENANT UN HALOALKYLE UTILISE COMME INHIBITEURS DE CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2005028454A1

  公开（公告）日：2005-03-31

  The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. Pharmaceutical compositions comprising these compounds and their use are also disclosed.

  该应用程序针对式(I)的卤代烷基取代化合物，其中R1、R1a、R2、R3、R4'和E如索权中所定义。这些化合物是半胱氨酸蛋白酶的抑制剂，特别是卡托普斯蛋白酶B、K、L、F和S，因此可用于治疗由这些蛋白酶介导的疾病。还公开了包含这些化合物的药物组合物及其用途。
• CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN
  申请人：Booth Robert

  公开号：US20120282267A1

  公开（公告）日：2012-11-08

  The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.

  本发明涉及使用抑制蛋白酶半胱氨酸蛋白酶的化合物的方法，特别是用于治疗骨癌的卡特普辛S和K以及可选地进一步的卡特普辛B和/或L。本发明涉及含有这些化合物的药物组合物，用于治疗骨癌和骨癌疼痛，尤其是与转移有关的疼痛。单一化合物可用于缓解疼痛、骨折伤，同时减少肿瘤生长、转移风险和/或癌症的侵袭性。
• Peptidic compounds as cysteine protease inhibitors
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：US20040127426A1

  公开（公告）日：2004-07-01

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是抑制B、K、L、F和S型猫蛋白酶，因此可用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和其制备方法。